Dr. Chapa’s Clinical Pearls.

Dr. Chapa’s Clinical Pearls
  • 5,0 (4)
  • SCIENCES
  • 2 FOIS PAR SEMAINE
Dr. Chapa’s Clinical Pearls.

Relevant, evidence based, and practical information for medical students, residents, and practicing healthcare providers regarding all things women’s healthcare! This podcast is intended to be clinically relevant, engaging, and FUN, because medical education should NOT be boring! Welcome...to Clinical Pearls.

  1. -2 J

    24-28 Hour Post-CS Discharge: New Data

    According to the UK’s National Institute for Health and Care Excellence (NICE; 2024), women who are S/P scheduled CS and recovering well, who are afebrile, and do not have complications, should be discharged early (after 24 h) and followed at home because this is not related to the readmission of the baby or mother. However, the first 24 hours after a C-section can be challenging, with many of the same challenges as a vaginal delivery PLUS the usual post-surgical issues: The mother will be adjusting to new parenthood, attempting breastfeeding, and fielding visitors; the incision will be sore, and pain may increase as anesthesia wears off. Is this postop plan coming to the USA? A soon to be published systematic review and meta-analysis (Dec 2024) in the AJOG MFM seems to favor that. Is this the new progression of the postop ERAS protocol? Listen in for details.

    29 min

  2. -4 J

    Q&A: ABRYSVO® Every Pregnancy? Clitoxin™?

    Welcome Back to another episode of "You ask, We Answer"! As Abrysvo (RSV vaccine) now has some time on the market, some women may find themselves with a subsequent pregnancy after first receiving the injection in the prior pregnancy. Is another RSV vaccine recommended with each pregnancy, like TDap? The answer to that question depends on where you live. We will discuss in this episode. PLUS, have you heard of CLITOXIN? Its a little botulinum toxin injected into the clitoris for "enhanced sexual response". Is that evidence-based? Is there data for that?! Listen in for details.

    42 min

  3. 26 OCT.

    Can Placental Volume on Sono Predict IUFD?

    Ultrasound assessment of placental volume has been proposed as an important aspect of prenatal care. It involves measuring the size and volume of the placenta, which may provide critical information regarding fetal health and development. Abnormal placental volume can be associated with various complications such as FGR, preeclampsia, and other pregnancy-related conditions. Some advocates suggests the volume and vascularity of the first trimester placenta may be linked to the most devasting adverse pregnancy outcomes which is stillbirth. Social Media posts have been advocating and endorsing the measurement of placental volume antenatally as a stillbirth prevention strategy. Is this evidence-based? It’s very controversial. Nonetheless, we have principles from the AIUM. ISUOG, ACOG, and SMFM to guide us here. Listen in for details.

    51 min

  4. 24 OCT.

    New AHA/ASA 2024 Guidance: WH Focus

    Stroke is also a leading cause of adult-onset disability; among individuals who survive 6 months, almost half are dependent in at least 1 activity of daily living. In October 2024, the AHA/ASA released their 2024 Primary Prevention of Stroke guidance. This document has a striking focus on women's health, namely adverse pregnancy outcomes and certain gynecological conditions (Endometriosis, POI, PCOS). Listen in for details.

    28 min

  5. 23 OCT.

    The Enigma of Endo and Early Birth

    Several observational studies have suggested that women with endometriosis have a slightly increased risk for preterm birth. The cause seems to be related to factors associated with pathogenesis of endometriosis, such as inflammation, reactive oxygen species, progesterone resistance, and alterations in the junctional zone of uterus leading to the shallow invasion of the placenta and to preterm birth. But is this association firmly established? It is actually more an enigma than solid evidence. In October 2024, a new cohort study in Fertility Sterility is questioning this relationship. These results are a contrast to the findings of a meta-analysis published in January 2022, which itself conflicted with results of a French observational study published the following month, February 2022. It’s the perpetual problem and enigma of whether endometriosis is associated with PTB, or not! Listen in for details.

    33 min

  6. 20 OCT.

    Insulin Initiation Made Easy

    In November's Green Journal, Drs Amy Valent and Linda Barbour will publish their Clinical Expert Series (CES) on insulin management in GDM and Type 2 DM in pregnancy. This is a FANTASTIC document and is our subject matter in this episode. Here, we will give clinical pearls for insulin initiation in pregnancy based on 3 regimens (NPH/Reg; NPH/RAAs; Basal-Bolus) and their initiation in an easy to follow format. Congratulations to Drs Valent and Barbour on a wonderful CES.

    47 min

  7. 19 OCT.

    The OCP Makes You Gay?

    The relationship between hormonal birth control and sexual orientation has been a topic on social media channels and threads; it is a discussion of controversy. It is essential to clarify that the hormonal birth control pill itself does not determine or change an individual's sexual orientation. While there is evidence to suggest that hormonal birth control can influence sexual desire and partner preferences, there is insufficient data to support the idea that it can change a person's sexual orientation. Sexual orientation is a complex interplay of biological, environmental, and social factors, and current scientific consensus does not support the idea that hormonal contraceptives influence one's sexual orientation. Where did this concept come from? Are there large-scale studies which address this? Listen in for details.

    24 min

  8. 16 OCT.

    Miso for EPF With Prior CSs?

    Early pregnancy failure (EPF), pregnancy loss in the first trimester, is a common pregnancy complication, with 15 to 20% of clinically recognized pregnancies ending in the first trimester. It is not uncommon for women with one or more cesarean sections, or myomectomies, to present with EPF. Options for treatment of early pregnancy failure include expectant management, surgical management (D&C), or medical management with medications such as misoprostol (miso). However, the limited information available regarding miso with EPF in those with prior uterine surgery may complicate the counseling of these women. What does the ACOG say about misoprostol use in the first trimester for these patients? Is misoprostol safe for EPF in women with 2 prior cesareans? In this episode, we will explore the data for miso use in these cases with a focus on the first trimester, but also review the data for miso use in the early second trimester in those with a scarred uterus.

    37 min
Tout afficher (907)

Bande-annonce

Notes et avis

5
sur 5
4 notes

À propos

Relevant, evidence based, and practical information for medical students, residents, and practicing healthcare providers regarding all things women’s healthcare! This podcast is intended to be clinically relevant, engaging, and FUN, because medical education should NOT be boring! Welcome...to Clinical Pearls.

Informations

  • Créateur
    Dr. Chapa’s Clinical Pearls
  • Années d’activité
    2018 - 2024
  • Épisodes
    907
  • Classement
    Tout public
  • Copyright
    © Dr. Chapa’s Clinical Pearls
  • Site Web de l’émission
    Dr. Chapa’s Clinical Pearls.

Vous aimerez peut-être aussi

Pour écouter des épisodes au contenu explicite, connectez‑vous.

Suivez l’actualité de cette émission

Connectez-vous ou abonnez-vous pour suivre des émissions, enregistrer des épisodes et obtenir les dernières mises à jour.
Sélectionnez un pays ou une région

Afrique, Moyen-Orient et Inde

Asie-Pacifique

Europe

Amérique latine et les Caraïbes

Les États-Unis et le Canada